- Home
- CLOV vs ZYME Comparison
CLOV vs ZYME Comparison
Compare CLOV & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLOV | ZYME |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CLOV | ZYME |
|---|---|---|
| Price | $4.31 | $25.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $2.90 | ★ $38.90 |
| AVG Volume (30 Days) | ★ 4.4M | 419.7K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.03 | 33.33 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $1,924,308,000.00 | $105,965,000.00 |
| Revenue This Year | $52.59 | $183.10 |
| Revenue Next Year | $15.37 | N/A |
| P/E Ratio | $42.70 | ★ N/A |
| Revenue Growth | ★ 40.34 | 38.87 |
| 52 Week Low | $1.58 | $13.60 |
| 52 Week High | $5.59 | $29.75 |
Technical Indicators
Market Signals| Indicator | CLOV | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 44.41 | 60.66 |
| Support Level | $4.12 | $22.10 |
| Resistance Level | $5.19 | $26.92 |
| Average True Range (ATR) | 0.24 | 0.94 |
| MACD | -0.01 | 0.34 |
| Stochastic Oscillator | 12.15 | 89.15 |
Price Performance
Historical ComparisonAbout CLOV Clover Health Investments Corp.
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.